Study guide

11.4 Theft & Loss Reporting, Disposal, Reverse Distribution & Take-Back Receptacles

Oregon Multistate Pharmacy Jurisprudence Examination MPJE

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Overview & Oregon Legal Framework

1.1 Oregon MPJE Format, Fees, Blueprint & 2027 Changes 1.2 Federal–Oregon Legal Hierarchy, Agencies & the Board of Pharmacy

2 Chapter 2: Pharmacist & Pharmacist-in-Charge Responsibilities

2.1 Pharmacist Responsibilities, Supervision & Prohibited Practices 2.2 Pharmacist-in-Charge: Qualifications, Duties, Inventories & Self-Inspection

3 Chapter 3: Pharmacy Technicians, Interns & Preceptors

3.1 Pharmacy Technicians (COPT & PT): Licensure, Permitted Tasks & Limits 3.2 Pharmacy Interns & Preceptors: Licensure, Scope & Supervision

4 Chapter 4: Licensure, Renewal, Discipline & Impaired Practitioners

4.1 Pharmacist Licensure by Examination, Score Transfer & Reciprocity 4.2 License Renewal, Continuing Pharmacy Education & Lapse Rules 4.3 Grounds for Discipline, Sanctions & Mandatory Reporting Deadlines 4.4 Impaired Practitioners & the Health Professionals' Services Program (HPSP)

5 Chapter 5: Prescriber Authority & Prescription Requirements

5.1 Prescriber Authority, DEA Registration & Out-of-State Prescriptions 5.2 Non-Controlled Prescriptions: Required Elements, Signatures, Expiration & Refills 5.3 Controlled Substance Prescriptions: Schedules II–V, EPCS, Emergency Orders & Oregon's CV Limit 5.4 Drug-Use Limitations & Special Prescriptions: REMS, Death with Dignity, EPT & Standing Orders 5.5 Legitimate Medical Purpose, Corresponding Responsibility & Red Flags

6 Chapter 6: Pharmacist Clinical Services & Prescriptive Authority

6.1 CDTM, Clinical Pharmacy Agreements, MTM & Laboratory Testing 6.2 Pharmacist Prescribing: Statewide Protocols, the Formulary & General Requirements 6.3 Pharmacist Prescribing of Hormonal Contraception (ORS 689.689) 6.4 Tobacco Cessation Protocol: Training, Screening, NRT & Non-NRT Prescribing 6.5 Vaccine Prescribing & Administration: Age Floors, Protocols, Training & ALERT IIS 6.6 Opioid Overdose Reversal & MOUD: Naloxone Prescribing, Standing Orders, Immunity & Buprenorphine

7 Chapter 7: Counseling, Language Access & Confidentiality

7.1 Patient Counseling: Triggers, Who May Offer or Accept a Refusal & Documentation 7.2 Language Access & Accessibility: Dual-Language Labels, Registry Interpreters & Prescription Readers 7.3 Patient Confidentiality: Oregon Rules, HIPAA, Part 2 & PDMP Privacy

8 Chapter 8: The Dispensing Process

8.1 Prospective Drug Utilization Review: Oregon's Eight Categories, Documentation & Who May Perform It 8.2 Oregon PDMP: Reporting Within 72 Hours, Covered Drugs, Access & Confidentiality 8.3 Prescription Transfers: Oregon's Next-Business-Day Duty & Federal Controlled Substance Limits 8.4 Dispensing Exceptions: 72-Hour Emergency Refills, Continuation of Therapy, Insulin & Declared Emergencies 8.5 Partial Fills: Schedule II (72-Hour, 30-Day CARA & 60-Day LTCF/Terminal) and Schedules III–V 8.6 Prescription Labeling: Oregon Elements, Physical Description, Expiration Dating & Med Paks 8.7 Packaging: PPPA Child-Resistant Containers, Waivers, Exemptions & Oregon's New-Container Rule 8.8 Conditions Prohibiting Dispensing, Quarantine, Returned Drugs & Charitable Reuse

9 Chapter 9: Nonprescription & Restricted Products

9.1 Nonprescription Drugs: Outlet Registration, Drug Facts Labeling & OTC Packaging 9.2 Dispensing-Restricted Nonprescription Products: Pseudoephedrine, Exempt Schedule V & Others

10 Chapter 10: Product Selection: Generic & Biologic Substitution

10.1 Product Selection: Generic Substitution (ORS 689.515) & Biologic Interchange (ORS 689.522)

11 Chapter 11: Acquisition, Records, Inventories & Loss Reporting

11.1 Ordering & Acquiring Controlled Substances: DEA Registration, Form 222, CSOS & the 5% Rule 11.2 Distribution Records, DSCSA, Recalls & Oregon Record Retention 11.3 Controlled Substance Inventories: Oregon's 367-Day, 93-Day, 31-Day & 15-Day Rules 11.4 Theft & Loss Reporting, Disposal, Reverse Distribution & Take-Back Receptacles

12 Chapter 12: Pharmacy Operations, Storage, Security & Special Practice Settings

12.1 Pharmacy Operations: Pharmacist Presence, Policies, Equipment, Signage, Hours & Closures 12.2 Drug Storage & Cold Chain: Temperatures, Monitoring Plans, Excursions & Vaccine Units 12.3 Security & Non-Pharmacist Access: Keys, Double Set-Ups, Institutional Night Access & DEA Controls 12.4 Hazardous Drugs: NIOSH 2024 List, USP 800 Controls, Assessment of Risk & Disposal 12.5 Compounding: OAR 855-183 (June 2026), USP 795/797/800, 503A vs. 503B & Beyond-Use Dates 12.6 Delivery of Drugs: Depots, Mail Delivery, Prescription Lockers, Kiosks & Mobile Pharmacies 12.7 Central Fill, Remote Processing, Telework & Remote Dispensing Site Pharmacies

13 Chapter 13: Drug Outlet Registration, Inspection & Institutional Practice

13.1 Drug Outlet Classes, Registration, Changes of Ownership/Location/Name & Non-Resident Pharmacies 13.2 Inspections, Self-Inspection Forms & Discipline of Drug Outlets 13.3 Institutional & Long-Term Care Practice: Drug Rooms, Night Access, E-Kits, ADCs & ED Prepacks

11.4 Theft & Loss Reporting, Disposal, Reverse Distribution & Take-Back Receptacles

Key Takeaways Explain This Topic AI

An Oregon pharmacy must report a confirmed significant drug loss, or any controlled substance loss related to suspected theft, to the Board within 1 business day by email.

DEA must be notified in writing within 1 business day of discovering a theft or significant loss, and DEA Form 106 must be filed within 45 days.

Schedule II stock goes to a reverse distributor on a DEA Form 222 issued by the reverse distributor; Schedule III–V transfers use invoices.

Oregon take-back receptacles must be in view of but not behind the pharmacy counter, and the pharmacy must notify the Board within 30 days of starting or ending a program.

Two employees must handle collection-receptacle liners, and deposited drugs may never be counted, sorted or accepted by hand from patients.

Last updated: October 2026

Why this matters

Area 4.2 covers "reporting" and the "disposal of hazardous drugs" alongside controlled substances. Theft and loss reporting has two simultaneous clocks, Board and DEA. Disposal and take-back have strict handling rules. Oregon adds a one-business-day Board report and specific take-back placement and notice rules.

Reporting theft or significant loss

To whom Deadline and content Source

Oregon Board of Pharmacy Without undue delay, but within 1 business day of a confirmed significant drug loss , or any loss related to suspected theft of a controlled substance . Email pharmacy.druglossreporting@bop.oregon.gov with "Controlled Substance Loss Notification" in the subject line OAR 855-115-0115; OAR 855-104-0010; OAR 855-041-1030

DEA Field Division In writing within 1 business day of discovering a theft or significant loss of any controlled substance 21 CFR 1301.76(b)

DEA Form 106 File a complete and accurate DEA Form 106 electronically within 45 days after discovery 21 CFR 1301.76(b)

Oregon's rule also covers confirmed significant losses of drugs generally , not only controlled substances. Its suspected-theft trigger covers any controlled-substance loss related to suspected theft, even a small one.

Is a loss "significant"? (21 CFR 1301.76(b))

DEA lists factors to consider:

The actual quantity lost in relation to the type of business.

The specific substances lost.

Whether the loss can be tied to access by particular people or to unique activities.

A pattern of losses over time, and the results of efforts to resolve them.

Whether the drugs are likely candidates for diversion.

Local trends and other signs of diversion potential.

In-transit losses are generally reported by the supplier that shipped the drugs, unless the purchaser has signed for the delivery. Breakage or spillage is not treated as theft. Witnessed, non-recoverable breakage is documented on DEA Form 41 with two witnesses, and any recoverable product is quarantined and destroyed through proper channels.

Disposing of pharmacy stock

Reverse distributors: the usual route for outdated, damaged or recalled controlled-substance stock. Schedule II transfers need a Form 222 (or CSOS order) issued by the reverse distributor to the pharmacy. Schedule III–V transfers are documented by invoice . The reverse distributor handles destruction and files the required DEA records. The pharmacy keeps its transfer records (3 years in Oregon).

DEA Form 41 documents the destruction of controlled substances by a registrant, for example destruction of inventory on site where permitted, with witnesses.

Oregon: drugs must be disposed of under state and federal law (OAR 855-041-1025). Hazardous and pharmaceutical waste disposal must be covered in written policies (OAR 855-041-1040). Quarantined controlled substances awaiting disposal must remain secured and are counted in the inventory.

Damaged inventory after a disaster may be treated as adulterated. Controlled-substance losses are reported to DEA on Forms 41, 106 or 107 as appropriate (OAR 855-007-0120).

Patient take-back: collection receptacles

Pharmacies may register with DEA as authorized collectors (21 CFR 1317.40) and install collection receptacles for ultimate users' Schedule II–V controlled substances and non-controlled drugs, which may be commingled.

Federal requirement (21 CFR 1317.75) Oregon add-on (OAR 855-041-1046)

Inside the registered location, in immediate proximity of the area where controlled substances are stored and an employee is present (visible from the pharmacy counter) Inside the retail drug outlet, accessible to the public and in view of, but not behind, the pharmacy counter

Securely fastened to a permanent structure; locked outer container; removable inner liner; slot that admits but doesn't allow removal Adequate security, installation, maintenance and liner tracking , with double signatures where required

Opening locked when no employee is present (for example, after pharmacy hours) Documented personnel training and accountability

Two employees install and remove inner liners. Deposited drugs are never counted, sorted, inventoried or handled Notify the Board within 30 days of starting or ending a collection program

Only ultimate users (or other authorized non-registrants) deposit their own drugs; staff may not take drugs from patients Pharmacies may get a free take-back box through Oregon's DEQ-overseen drug take-back program

Warning

A patient hands a bag of leftover opioids across the counter to a technician "for disposal." Under federal collection rules and OAR 855-041-1045(1), staff may not accept it. The patient must deposit it personally in the collection receptacle, or use a mail-back envelope or take-back event.

Exam scenario

During a 93-day Schedule II reconciliation on a Monday, an Oregon PIC finds 120 oxycodone 30 mg tablets missing, with a pattern pointing to one shift. The PIC must notify the Board by email within one business day (by Tuesday) and DEA in writing within one business day , then file DEA Form 106 within 45 days . The PIC documents the discrepancy and investigation. If a licensee is terminated as a result, the outlet reports the termination within 10 working days . Separately, the pharmacy's expired hydromorphone goes to a reverse distributor, which issues a Form 222 for the Schedule II transfer.